Home » General Medicine » STRIVE Trial: Erenumab for Episodic Migraine

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

STRIVE Trial: Erenumab for Episodic Migraine

The STRIVE trial introduced Erenumab, a once monthly self injectable drug for prevention of episodic migraine. It’s calcitonin-gene-related peptide (CGRP) antagonist. It is recently approved by FDA for its use in migraine. Check out the STRIVE trial visual summary and visual abstract to understand how effective was Erenumab for episodic migraine.

Source: NEJM

Subscribe via email